FAP and ovarian carcinoma: Several therapies are targeting CAFs in ovarian cancer: (1) direct deletion FAP+ fibroblasts; (2) reverting the activated CAFs into a quiescent state; (3) targeting CAF-specific pathways (Chen and Song, 2019; Barrett and Puré, 2020; Truffi et al., 2020).